BDBM725530 US12583836, Compound 279::US20250074891, Compound 280

SMILES C[C@H](Oc1cc(-c2n[nH]c(Nc3cnccn3)c2C(N)=O)ccc1CS(=O)(=O)C(F)F)c1ncco1

InChI Key InChIKey=QPPYZEONSBNIQU-UHFFFAOYSA-N

Data  6 Kd

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 725530   

TargetMixed lineage kinase domain-like protein(Human)
Anaxis Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 725530BDBM725530(US20250074891, Compound 280 | US12583836, Compound...)
Affinity DataKd: <10nMAssay Description:Kinase assays. For most assays, kinase-tagged T7 phage strains were grown in parallel in 24-well blocks in an E. coli host derived from the BL21 stra...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/9/2025
Entry Details
US Patent

TargetMixed lineage kinase domain-like protein(Human)
Anaxis Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 725530BDBM725530(US20250074891, Compound 280 | US12583836, Compound...)
Affinity DataKd: <10nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/3/2026
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 3(Human)
Anaxis Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 725530BDBM725530(US20250074891, Compound 280 | US12583836, Compound...)
Affinity DataKd: >3.00E+4nMAssay Description:Kinase assays. For most assays, kinase-tagged T7 phage strains were grown in parallel in 24-well blocks in an E. coli host derived from the BL21 stra...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/9/2025
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 3(Human)
Anaxis Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 725530BDBM725530(US20250074891, Compound 280 | US12583836, Compound...)
Affinity DataKd: >3.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/3/2026
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Anaxis Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 725530BDBM725530(US20250074891, Compound 280 | US12583836, Compound...)
Affinity DataKd: >3.00E+4nMAssay Description:Kinase assays. For most assays, kinase-tagged T7 phage strains were grown in parallel in 24-well blocks in an E. coli host derived from the BL21 stra...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/9/2025
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Anaxis Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 725530BDBM725530(US20250074891, Compound 280 | US12583836, Compound...)
Affinity DataKd: >3.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/3/2026
Entry Details
US Patent